Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15051568
Abstract: Simple Summary We aimed to evaluate the impact of therapeutic modifications of atezolizumab (Atezo) plus bevacizumab (Bev) therapy (Atezo/Bev) in the case of intolerable adverse events on the prognosis of patients with unresectable hepatocellular carcinoma.… read more here.
Keywords: overall survival; atezo bev; discontinuation atezo; discontinuation ... See more keywords